Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum F VGM
Zacks News
CORT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CORT vs. ZTS: Which Stock Is the Better Value Option?
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
by Zacks Equity Research
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline
by Zacks Equity Research
Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.
Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns
by Zacks Equity Research
Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch. Sole dependence on Firdapse for growth remains a concern.
Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.
Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.
Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -14.29% and -18.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down
Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.
Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon
Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant
by Zacks Equity Research
Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.
Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.
AMRX or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. CORT: Which Stock Is the Better Value Option?
Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.
Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season
by Zacks Equity Research
Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for November 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View
by Zacks Equity Research
Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.
Corcept Therapeutics (CORT) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?